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123 I]β-CIT binding; and to determine the sample size and frequency of SPECT imaging required to demonstrate a significant effect of a putative neuroprotective agent. Methods: A group of 50 early stage Parkinson's disease patients was examined. Two SPECT imaging series were obtained, 12 months apart. The mean annual change in the ratio of specific to non-specific [
123 I]β-CIT binding to the striatum, putamen, and caudate nucleus was used as the outcome measure.
Results: A decrease in [ 123 I]β-CIT binding ratios between the two images was found in all regions of interest. The average decrease in [
123 I]β-CIT binding ratios was about 8% in the whole striatum, 8% in the putaminal region, and 4% in the caudate region. Comparison of scans done in nine patients under two different conditions-in the off state and while on drug treatment-showed no significant alterations in the expression of striatal dopamine transporters as measured using [
123 I]β-CIT SPECT. Power analysis indicated that to detect a significant (p < 0.05) effect of a neuroprotective agent with 0.80 power and 30% of predicted protection within two years, 216 patients are required in each group when the effects are measured in the whole putamen. T he pathophysiological hallmark of Parkinson's disease is a slow, progressive degeneration of dopaminergic neurones in the substantia nigra. 1 Standard therapeutic interventions are aimed at replenishing empty dopamine stores with levodopa, or substitution with dopamine receptor agonists. However, in the long term this symptomatic treatment fails. Various neuroprotective agents are currently being developed with the intention of treating the cause of the disease and thereby delaying the degeneration of dopaminergic neurones. To evaluate the effectiveness of such agents, it is important to develop methods that can reliably measure progression of dopaminergic degeneration. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) could prove to be objective tools for measuring the effectiveness of putative neuroprotective agents and monitoring disease progression. For example, recent studies using [ 11 were used to assess the stage and severity of the disease at the time of first imaging. A detailed clinical and demographic description is given in table 1. Each patient was imaged on two occasions, with a mean scan to scan interval of 51 (7) weeks.
All patients gave written informed consent to the research protocol, which was approved by the medical ethics committee of the hospital.
Drug treatment
All patients in the "progression study" were drug-naive at the time of the first scan, after which dopaminergic treatment (levodopa or a D 2 receptor agonist) was initiated.
A previous study in patients with Parkinson's disease showed no significant effects of subchronic administration of Six of the patients had not previously received D 2 receptor agonist treatment at the time of the first imaging. In these six patients (protocol A), treatment with a D 2 receptor agonist (pergolide or pramipexol) was started one day after the baseline imaging, following an increasing schedule up to 2.0 mg/day for pergolide and 2.25 mg/day for pramipexol (table  2) . In these patients, the second imaging was done after four to five weeks while they were on treatment with the D 2 receptor agonist. In the last week before the second imaging, the daily dose of the D 2 receptor agonist was maintained stable.
The other three patients in the D 2 receptor agonist assessment study were first imaged while on a stable dose of pergolide, which had been given as monotherapy for about a year. After the initial imaging, the drug was withdrawn for two to three weeks and the second imaging was done (protocol B).
The effects of D 2 receptor agonist treatment on [ 
SPECT camera
The Strichman Medical Equipment 810X system (Strichman Inc, Medfield, Massachasetts, USA) was used for SPECT imaging. The transaxial resolution of this camera is 7.6 mm full width at half maximum of a line source in air. 16 The energy window was set at 135-190 keV. Data acquisition took place in a 128 × 128 matrix.
SPECT imaging
The patients were given potassium iodide orally to block the thyroid uptake of free radioactive iodide. [ 123 I]β-CIT (specific activity > 185 MBq/nmol; radiochemical purity > 99%) was injected intravenously at an approximate dose of 110 MBq.
123
I labelling, acquisition, attenuation correction, and reconstruction of images was done as described before. 6 The measured concentration of radioactivity was expressed as Strichman medical units (SMUs; 1 SMU = 100 Bq/ml).
Image acquisition was always started 24 hours after the injection of the radioligand. Slices were acquired during 300 s periods after positioning the patient's head in the camera, with beams from gantry mounted lasers oriented parallel to the canthomeatal (CM) line, from the CM line to the vertex using an interslice distance of 10 mm. Imaging was always done using the same equipment and following the same protocol.
During the second image session, all efforts were made to ensure that the patient's head in the camera conformed to the position used during the first image session. To achieve this, the distances from the meatuses of the ears and from the orbital angles to the position of the laser beams were recorded. In previous studies we showed that this procedure is highly reproducible. 17 Data processing For analysis of striatal [ 123 I]β-CIT binding, two transverse slices representing the most intense striatal binding were summed. A standard region of interest (ROI) template, constructed according to a stereotactic atlas and including fixed regions for caudate nucleus, putamen, whole striatum, and occipital cortex, was placed bilaterally on the combined image, as described previously. 16 Estimates of specific striatal binding were made by subtracting occipital counts (nonspecific binding) from total striatal counts. The ratio of specific to non-specific striatal [ 123 I]β-CIT binding was then calculated by dividing the specific striatal uptake by the occipital uptake. These binding ratios were also used to calculate comparable ratios for caudate nucleus and putamen. 18 
Statistics
The relation between the initial [ 123 I]β-CIT binding ratios and UPDRS was measured using the Spearman rank correlation. A paired samples two tailed t test was used to examine the change between baseline and follow up imaging results. The mean annual rate of decline in [ 123 I]β-CIT binding ratios was Power analysis was undertaken to estimate the sample size and the scan interval required to demonstrate a significant neuroprotective effect of agents with various degrees of predicted protection. The analysis assumed an annual rate of dopaminergic degeneration based on the data obtained in the present study. The standard deviation of the mean annual change in [ 123 I]β-CIT binding was used as a measure of variance. Sample size was determined using Altman's nomogram. 19 Significance was assumed at a probability (p) value of < 0.05. In the case of multiple comparisons the Bonferroni correction was used.
RESULTS
No significant difference in age, disease severity, or [ 123 I]β-CIT binding measures was found between male and female subjects.
Progression of dopaminergic degeneration
The baseline ratios of specific to non-specific [ (table 3) . There was a significant decrease in specific to non-specific [ 123 I]β-CIT binding ratios in the whole, ipsilateral, and contralateral striatum and putamen, this being most obvious in the whole putamen. The relative annual rate of decrease in [ 123 I]β-CIT binding ratios was about 8% in striatal regions, 8% in putaminal regions, and 4% in caudate regions.
No correlation was found between the rate of progression in all regions of interest and the baseline binding ratios, the duration of Parkinson's disease symptoms, or the severity of the disease expressed by the UPDRS motor score. 
Power analysis
Power analysis indicated that in order to detect a significant effect of a neuroprotective agent with 0.80 power and 50% of predicted protection within two years, 78 patients would be required in each group when the effects are measured by means of changes in [ 123 I]β-CIT binding ratios in the whole putamen. For a trial with an agent with 30% of predicted neuroprotection, 216 patients would be required. Assuming a linear decline in dopaminergic function, it was calculated that extending the scanning interval to five years reduces the required sample size to 13 patients in each group for a trial with an agent with 50% of predicted protection, and to 35 patients in each group for a trial with an agent with 30% of predicted protection (table 4) .
DISCUSSION

This is one of the few [
123 I]β-CIT SPECT studies done so far to investigate the value of the technique in monitoring the progression of Parkinson's disease by serial evaluation in a large group of patients with early stage disease. [20] [21] [22] In agreement with other studies, we found significant correlations between [ 123 I]β-CIT binding ratios and UPDRS motor score in drug-naive patients. 5 6 The binding ratios obtained at the first series of imagings were approximately 35% of control for the putamen and 55% of control for the caudate nucleus. These results are in line with the findings of previous studies, [5] [6] 7 These investigators showed that [ 123 I]β-CIT SPECT imaging is a highly reproducible measure of striatal dopamine transporters in Parkinson's disease and suggested that the method would be suitable for the serial evaluation of dopaminergic degeneration.
In the present study, we showed that the mean annual rate of dopaminergic degeneration in striatum, and subregionally in the putamen, reached statistical significance at about 8%. These findings fit well with the results of recent PET and SPECT studies. 26 and found approximately an 8% decline per decade. In this context, our results show that the rate of progression of dopaminergic degeneration is much faster in Parkinson's disease than in normal aging.
The mean rate of progression of the dopaminergic degeneration in the caudate was slower than in the putamen. This is in agreement with the results of cross sectional SPECT and PET studies, indicating that the function of the caudate nucleus in the early Parkinson's disease stages is relatively spared.
Though the patients in the present study were under dopaminergic drug treatment (levodopa or a D 2 agonist) at the time of the second imaging, Laruelle et al showed that infusion of high dose levodopa failed to displace striatal [ Several techniques are now available for imaging nigrostriatal dopaminergic neurones (for a review, see Booij and colleagues 29 ). In the present study, we used a radiotracer which binds to the dopamine transporter. This transporter is located exclusively on nerve terminals of dopaminergic cells. Several studies have shown that the loss of striatal dopamine transporters in Parkinson's disease is in concordance with the loss of nigrostriatal dopamine neurones. 30 In addition, necropsy studies of patients with Parkinson's disease have shown that measurements of dopamine transporter density are highly correlated with striatal dopamine levels. 31 Experimental studies in rats and monkeys have also validated the fact that drug induced losses of nigrostriatal cells are correlated with loss of dopamine transporters, as measured by ]β-CIT SPECT studies have shown loss of dopamine transporters in Parkinson's disease, and correlations between motor signs and severity of loss of these transporters. 5 6 These studies have shown the validity of using dopamine transporter imaging to assess the integrity of presynaptic dopaminergic nerve terminals in Parkinson's disease. In fact, β-CIT SPECT assesses the expression of dopamine transporters on surviving dopaminergic cells. Recently, an important study by Lee et al suggested that the dopamine transporter is downregulated on surviving dopaminergic neurones in Parkinson's disease. 34 This observation is in line with experimental studies suggesting that the loss of dopamine neurones is functionally compensated by an increase in synthesis and release of dopamine from surviving dopamine nerve terminals, as well as by a reduced rate of dopamine inactivation in presynaptic dopamine nerve terminals. 35 In the light of all these data, we cannot exclude the possibility in the present study that the loss of dopamine transporters in Parkinson's disease results from a combination of cell loss (and consequently loss of dopamine transporters) and downregulation of dopamine transporters on surviving neurones. However, if the loss of β-CIT binding to dopamine transporters in Parkinson's disease can be explained partly by downregulation, it seems unlikely that this regulation will disappear, whereas degeneration of dopaminergic neurones ]β-CIT binding in this region is the most sensitive to changes in the rate of dopaminergic degeneration. We estimated that, in order to show a significant effect of a neuroprotective agent with 0.80 power and 50% of predicted protection within two years, 78 patients are required in each group when the effects are measured in the whole putamen. For a trial with an agent with 30% of predicted protection, 216 patients are required. As expected, extending the scanning interval to five years reduces the required sample size remarkably. All estimations are based on the assumption of a constant rate of dopaminergic degeneration through the initial course of the disease. The linear evolution seems a reasonable approximation for the relatively brief period of time involved in the present study. However, if the degeneration shows an exponential course, slowing down in the later disease stages (a reasonable hypothesis), then a larger sample size would be required to detect the same neuroprotective effect.
Conclusions
Our study shows that [ 
